The SFC-backed vaccine developer has wrapped up its series B-2 round after holding an initial close in early 2019.
Aivita Biomedical, a US-based stem cell vaccine developer backed by chemicals producer SFC, raised $25m in series B-2 round from undisclosed life sciences investment firms yesterday.
Founded in 2016, Aivita is developing personalised vaccines for the treatment of cancer and the prevention of the covid-19 virus and retinal degenerative diseases.
The company will launch a skincare line in the United States this month that will pledge the proceeds of its sales towards cancer treatment.
The funding will be used to…
